Diagnosis of diseases associated with COX-2 expression
OwnerHildegard Schuller, George Kabalkainventors
Life of this patent
Estimating the term…
Abstract
Derivatives of cyclooxygenase-2 inhibitor compounds are made incorporating a label that can be identified upon administration into the body of a mammal and subsequent binding of the compounds with cyclooxygenase-2 that is overexpressed due to a disease condition such as cancer.
Claims38
A method for diagnosing a bodily disorder in a mammalian subject, which bodily disorder is associated with an increased expression of cyclooxygenase-2 (COX-2), comprising administering to the subject a labeled chemical compound that binds to the COX-2, permitting the labeled chemical compound to circulate within the body of the subject and to bind to COX-2 that is present within the body of the subject, and determining one or more areas within the body where the labeled chemical compound has bound to COX-2.
A method for adhering a radioactive atom to a cyclooxygenase-2 (COX-2) enzyme molecule within the body of a subject comprising obtaining a radiolabeled chemical compound that is a COX-2 inhibitor and which COX-2 inhibitor binds to the COX-2 enzyme, administering the radiolabeled COX-2 inhibitor to a subject, and permitting the administered radiolabeled COX-2 inhibitor to adhere to COX-2 enzyme molecules within the body.
A radiolabeled chemical compound which chemical compound is an inhibitor of cyclooxygenase-2 (COX-2) and wherein the chemical compound binds to the COX-2.
A method for determining if a patient is suffering from a bodily disorder that is associated with an increased expression of cyclooxygenase-2 (COX-2) comprising administering to the patient a labeled chemical compound that binds to the COX-2, permitting the labeled chemical compound to circulate within the body of the patient, and determining if there are present within the body of the patient one or more areas where the labeled chemical compound has bound to COX-2.
Dependencies are inferred from the claim text.